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 2
Abstract 26 
 27 
The extent to which HIV-1 clade B strains exhibit population-specific adaptations to host 28 
HLA alleles remains incompletely known, in part due to incomplete characterization of 29 
HLA-associated HIV-1 polymorphisms (HLA-APs) in different global populations. 30 
Moreover, it remains unknown to what extent the same HLA alleles may drive significantly 31 
different escape pathways across populations. As the Japanese population exhibits 32 
distinctive HLA class I allele distributions, comparative analysis of HLA-APs between 33 
HIV-1 clade B-infected Japanese and non-Asian cohorts could shed light on these questions. 34 
However HLA-APs remain incompletely mapped in Japan. In a cohort of 430 35 
treatment-naïve Japanese with chronic HIV-1 clade B infection, we identified 284 36 
HLA-APs in Gag, Pol and Nef using phylogenetically-corrected methods. The number of 37 
HLA-associated substitutions in Pol, notably those restricted by HLA-B*52:01, was weakly 38 
inversely correlated with plasma viral load (pVL), suggesting that the transmission and 39 
persistence of B*52:01-driven Pol mutations could modulate pVL. Differential selection of 40 
HLA-APs between HLA subtype members, including those differing only with respect to 41 
substitutions outside the peptide-binding groove, was observed, meriting further 42 
investigation as to their mechanisms of selection. Notably, two-thirds of HLA-AP identified 43 
in Japan had not been reported in previous studies of predominantly Caucasian cohorts, and 44 
were attributable to HLA alleles unique to, or enriched in, Japan. We also identified 71 45 
cases where the same HLA allele drove significantly different escape pathways between 46 
Japan versus predominantly Caucasian cohorts. Our results underscore the distinct global 47 
evolution of HIV-1 clade B as a result of host population-specific cellular immune 48 
pressures.  49 
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Importance section 50 
 51 
CTL escape mutations in HIV-1 are broadly predictable based on the HLA class I alleles 52 
expressed by the host. Because HLA allele distributions differ among worldwide 53 
populations, the pattern and diversity of HLA-associated escape mutations are likely to be 54 
somewhat distinct to each race and region. HLA-associated polymorphisms (HLA-APs) in 55 
HIV-1 have previously been identified at the population level in European, North American, 56 
Australian and African cohorts, however, large-scale analyses of HIV-1 clade B-specific 57 
HLA-APs in Asians are lacking. Differential intra-clade HIV-1 adaptation to global 58 
populations can be investigated via comparative analyses of HLA-associated 59 
polymorphisms across ethnic groups, but such studies are rare. Here, we identify HLA-APs 60 
in a large Japanese HIV-1 clade B cohort using phylogeneticaly-informed methods and 61 
observe that the majority of them had not been previously characterized in predominantly 62 
Caucasian populations. Results highlight HIV’s unique adaptation to cellular immune 63 
pressures imposed by different global populations.   64 
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Introduction 65 
 66 
HIV CTL escape occurs in a manner that is highly reproducible in context of the HLA 67 
class I alleles expressed by the host (1-8). By extension, HIV sequences circulating in a 68 
given host population will exhibit polymorphisms that reflect the HLA allele distribution of 69 
that population (9). Because HLA class I allele distributions differ among racial and ethnic 70 
groups worldwide (10), the pattern and diversity of HLA-associated escape mutations is 71 
also likely to be somewhat distinct to each race and region. Numerous population-based 72 
studies identifying HLA-associated polymorphisms (HLA-APs) have been conducted in 73 
European, North American, Australian, and African cohorts (2, 6, 8). However, comparably 74 
fewer have been undertaken in Asian cohorts, where HIV-1 prevalence is also substantial 75 
(11). Since Asian populations differ in their HLA allele distributions from the cohorts 76 
previously studied, it is important to identify and analyze HLA-APs to achieve a better 77 
understanding of HIV-1 pathogenesis in Asia and to inform future HIV vaccine design 78 
efforts targeted to these populations. The Japanese epidemic is somewhat unique in Asia. 79 
While clades A/E and C predominate in many Asian countries (12-14), the Japanese HIV-1 80 
epidemic comprises 80% clade B infections (12). As such, the analysis of Japanese cohorts 81 
also provides the opportunity to undertake comparative analyses of HLA-APs between 82 
Asian and non-Asian populations infected with HIV clade B. 83 
Previous studies have investigated differential HLA-driven HIV evolution across human 84 
populations. For example, a study of HLA-specific adaptations in HIV Pol in a Mexican 85 
cohort identified “unique” HLA-APs in this population that were not present in an 86 
international cohort from Canada, the USA and Australia, even though both cohorts 87 
harbored HIV clade B (15). Most of the unique Mexican HLA-APs were restricted by HLA 88 
alleles particular to this population (e.g. HLA-B*39) but that were underrepresented or 89 
absent in the international cohort (15). This study therefore illustrates population-specific 90 
HIV adaptation in its most intuitive manifestation: where distinctive HLA-associated 91 
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polymorphisms are observed in a population due to the presence (or comparatively higher 92 
frequency) of an HLA allele in this population compared to another.  93 
What remains unknown however, is the extent to which the same HLA allele may drive 94 
divergent escape pathways in different human populations. Two critical features are 95 
required to address this question. First, the identification of HLA-AP must be undertaken at 96 
the HLA subtype level. This is because the majority (>60%) of HLA-associated 97 
polymorphisms are best defined at the subtype-level (16) – even for closely related HLA 98 
subtype members that present the same or similar peptide epitopes (16, 17, 18 , 19). 99 
Comparative studies undertaken at allele-level (two-digit) resolution cannot disentangle 100 
whether population-specific HLA-AP are attributable to differential HLA subtype 101 
distributions between cohorts, or whether they are “true” cases where the same HLA 102 
subtype drives different escape pathways across populations. Indeed, a study investigating 103 
>500 Americans with chronic HIV-1 clade B infection observed distinct patterns of 104 
HLA-APs among White, Black, and Hispanic individuals that were likely attributable to the 105 
differential distribution of closely-related HLA subtypes among these groups (18) rather 106 
than true differential escape. The present study is therefore undertaken at subtype-level 107 
resolution. Secondly, the identification of population-specific escape pathways driven by 108 
the same HLA allele requires a method to do so. Here, we adapt phylogenetically-corrected 109 
statistical methods originally developed to assess differential escape among related HLA 110 
subtypes (17) and apply them to investigate differential escape across host populations. 111 
The present study is divided into two parts, each with a specific major objective. Our 112 
first objective was to identify and characterize HLA-AP in HIV-1 Gag, Pol, and Nef 113 
proteins in a cohort of 430 chronically clade B-infected Japanese individuals using 114 
phylogenetically-informed approaches (20), and to investigate their associations with 115 
clinical parameters (CD4+ T cell count and plasma viral load). Importantly, HLA 116 
genotyping (and thus HLA-AP identification) was undertaken at subtype-level resolution, 117 
allowing us to analyze the effect of genetic differences among closely-related HLA 118 
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subtypes on the selection of HLA-APs in the Japanese cohort as part of this objective. Our 119 
second major objective was to perform a comparative analysis of HLA-AP identified in 120 
Japan to those identified in a large international (Canada/USA/Australia) cohort of 121 
antiretroviral-naïve, chronically clade B infected, predominantly Caucasian individuals. As 122 
expected, a substantial proportion of Japanese HLA-AP were restricted by alleles unique to 123 
(or highly enriched in) Japan compared to the non-Asian cohort. Notably we also observed 124 
numerous cases where the same HLA allele drove significantly different – sometimes 125 
opposing – escape pathways in these two populations. Our results highlight HIV’s unique 126 
adaptation to cellular immune pressures imposed by different global populations. 127 
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Materials and Methods 128 
 129 
Ethics statement 130 
This study was approved as a part of “the study of immunological and virological 131 
analysis in HIV-1 infection (#540)” by the ethics committee for epidemiology and general 132 
study in the faculty of life science in Kumamoto University and the National Center for 133 
Global Health and Medicine. All studied individuals were adults. Written informed consent 134 
was obtained from all studied individuals according to the Declaration of Helsinki. 135 
 136 
Subjects 137 
Four-hundred-thirty treatment-naïve Japanese individuals with chronic HIV-1 clade B 138 
infection were enrolled in the National Center for Global Health and Medicine (NCGHM) 139 
from 2008 to 2011. HLA alleles of these individuals were determined at the 4-digit level by 140 
a probe-based sequence-specific oligonucleotide (SSO) typing method (HLA Laboratory, 141 
Kyoto, Japan). The median CD4+ T cell count (CD4 count) and plasma viral loads (pVL) at 142 
the first visit to NCGHM were 321 cells/μl (IQR: 190 to 440 cells/μl) and 25,000 copies/ml 143 
(IQR: 6,800 to 98,000 copies/ml), respectively. 144 
HLA-associated polymorphisms derived from the International HIV Adaptation 145 
Collaborative (IHAC) cohort, comprising 1,888 treatment-naïve individuals with chronic 146 
clade B infection from Canada, USA, and Western Australia (16), identified using identical 147 
methods, were used for comparison. The IHAC cohort comprises predominantly Caucasian 148 
individuals, with Asians making up less 5% of the total. The median CD4 count in IHAC 149 
was 260 cells/μl (IQR: 110 to 418 cells/μl). 150 
 151 
RT-PCR and sequencing of plasma HIV RNA 152 
HIV-1 viral RNA was extracted from plasma samples using either a QIAamp MinElute 153 
virus spin kit (Qiagen, Valencia, CA) or an EZ1 Virus Mini Kit v2.0 (Qiagen, Valencia, CA). 154 
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Reverse transcription was performed using random hexamers with the SuperScript III 155 
First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA). HIV-1 Gag, Pol, and 156 
Nef genes were amplified from cDNA by nested PCR using Taq DNA polymerase 157 
(Promega, Fitchburg, WI) and 10 primer pairs that were designed based on the clade B 158 
strain. For subjects with a viral load below 1000 copies/ml, RT-PCR was performed with 159 
region-specific primers using the SuperScript III One-Step RT-PCR System with Platinum 160 
Taq kit (Invitrogen, Carlsbad, CA). The 1st round PCR product was then used in the 2nd 161 
round PCR amplification using Taq DNA polymerase (Promega, Fitchburg, WI) and the 10 162 
primer pairs. The 2nd round PCR product was purified by using the ExoSAP-IT reagent 163 
containing Exonuclease I and alkaline phosphatase (GE Healthcare, Buckinghamshire). 164 
Gag, Pol, and Nef sequences were determined by using the BigDye Terminator v3.1 cycle 165 
sequencing kit (Applied Biosystems, Carlsbad, CA) and an ABI 3500 genetic analyzer 166 
(Applied Biosystems, Carlsbad, CA). Sequencing reactions were performed in both 5’ and 167 
3’ directions to yield a minimum of bidirectional coverage of all regions. Sequence data 168 
was then aligned by using SeqScape software (Applied Biosystems, Carlsbad, CA) based 169 
on the HXB2 reference sequence (K03455). Accession numbers are AB873205 to 170 
AB873601 (Gag), AB873908 to AB874270 (Pol), and AB873602 to AB873907 (Nef). 171 
 172 
Identification of HLA-associated polymorphisms 173 
HLA class I associated polymorphisms in HIV-1 (HLA-AP) can be identified in large, 174 
cross-sectional linked datasets of host (HLA) and HIV genotypes using statistical 175 
association approaches that identify viral polymorphisms significantly over- or 176 
under-represented in individuals harboring a specific HLA class I allele (1, 2, 4, 16-18, 21). 177 
HLA-APs that are over-represented in individuals harboring the relevant HLA are 178 
commonly referred to as “adapted” forms, while those under-represented in individuals 179 
harboring the relevant HLA are referred to as “nonadapted” forms (2, 18). As such, 180 
“nonadapted” and “adapted” forms can be conceptualized to represent the 181 
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“immunologically susceptible” and “escape mutant” forms, respectively, for the specific 182 
HLA allele in question at that HIV codon position. Statistical association approaches for the 183 
identification of HLA-AP also correct for the confounding influences of viral phylogeny, 184 
HIV codon covariation and linkage disequilibrium between HLA class I alleles (2, 16, 17, 185 
21). 186 
Associations between HLA class I alleles and HIV-1 amino acid polymorphisms in the 187 
Japanese and IHAC datasets were identified using a published phylogenetically-corrected 188 
logistic regression model that corrects for HLA linkage disequilibrium, HIV phylogeny, and 189 
HIV codon covariation as potential confounders (17, 20). Briefly, maximum likelihood 190 
phylogenetic trees were constructed using Gag, Pol and Nef sequences (one tree per gene), 191 
and a model of conditional adaptation was inferred for each observed amino acid at each 192 
codon. Amino acids are assumed to evolve independently along the phylogeny, until the 193 
tree tips (representing the present host). In each host, HLA-mediated selection and HIV 194 
amino acid covariation are directly modeled using weighted logistic regression, in which 195 
the individual’s HLA repertoire and covarying HIV amino acids are used as binary 196 
predictors and the bias is determined by the possible transmitted sequences as inferred by 197 
the phylogeny (17). To identify which factors (HLA and/or HIV covariation) contribute to 198 
selection pressure, we employ a forward selection procedure where the most significant 199 
association is iteratively added to the model, with p-values computed using the likelihood 200 
ratio test. We performed post-hoc filtering of the resulting HLA-associated polymorphisms 201 
list, restricting our output to instances in which at least 10 individuals carried the allele or 202 
polymorphism and at least 10 individuals did not carry the allele or polymorphism. 203 
Multiple tests were accounted for using q-values, the p-value analog of the false discovery 204 
rate (FDR) (22). The FDR is the expected proportion of false positives among results 205 
deemed significant at a given threshold; for example, at q < 0.2, we expect 20% of 206 
identified associations to be false positives. In the analyses identifying HLA-associated 207 
polymorphisms (HLA-AP), significance threshold of q < 0.2 was employed. 208 
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 209 
Statistical analysis 210 
Correlations between the total number of HLA-associated substitutions in each 211 
individual and clinical parameters (pVL and CD4 count) were performed using Spearman’s 212 
correlation. To count the total number of HLA-associated substitutions within a given 213 
HIV-1 sequence, we first identified all HIV-1 sites within that sequence identified as being 214 
associated with any HLA allele. The specific residue at each site was counted as 215 
“HLA-associated” if it matched any HLA-associated adapted form, or any residue other 216 
than a nonadapted form identified at that position. The HLA alleles expressed by the 217 
individual were not considered (unless specifically stated) – rather, our goal was to 218 
enumerate the number of HLA-AP associated with any HLA allele in each viral sequence. 219 
In analyses where host HLA alleles were not considered, HIV sites harboring residues that 220 
simultaneously represented a nonadapted and Adapted form associated with different HLA 221 
alleles were excluded from consideration. 222 
 223 
Detection of differential escape between closely-related HLA alleles, and between 224 
cohorts. 225 
Two types of differential escape were investigated. First, we investigated differential 226 
escape between closely-related HLA class I alleles, defined here as (four-digit) HLA 227 
subtype members belonging to the same (two-digit) allele group, in the Japanese cohort. 228 
Specifically, seven HLA allele groups (A*02, A*26, B*15, B*40, C*03, C*08, and C*14) 229 
for which a minimum of two subtype members were represented in the Japanese cohort, 230 
were investigated. For example, the HLA-A*02 allele group featured subtypes A*02:01, 231 
A*02:06 and A*02:07, while the A*26 allele group featured subtypes A*26:01 and 232 
A*26:03. For each allele group, we took the union of all HLA-AP identified for all subtype 233 
members of the group. Then, in a pairwise manner, we compared their strengths of 234 
selection between all HLA subtype members using a previously-described 235 
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phylogenetically-corrected interaction test (17). In this analysis, thresholds of p < 0.05, q < 236 
0.2 were used to define significance.  237 
Second, we investigated differential HLA-driven escape pathways between Japanese and 238 
IHAC cohorts. As outlined in the introduction, HLA-AP identified in human populations 239 
will differ to some extent due to the presence (or enrichment) of certain HLA alleles in one 240 
population versus another. However in this analysis we were specifically interested in 241 
identifying cases where the same HLA allele drove significantly different escape pathways 242 
in the two cohorts. To do this, we took the union of all HLA-AP identified in Japan and 243 
IHAC cohorts, that were restricted by HLA subtypes observed a minimum of 10 times in 244 
both cohorts. We then compared the strength of selection of each HLA-AP in a pairwise 245 
manner, between cohorts. The statistical methods used investigate differential escape 246 
between Japanese vs. IHAC cohorts are similar to those used to investigate differential 247 
escape between HLA subtype members (17), with some modifications as follows. Briefly, a 248 
phylogenetically-corrected logistic regression model is constructed using a single HLA 249 
allele as a predictor. Using a likelihood ratio test, we then compare this model to a more 250 
expressive one that includes an additional interaction term that is 1 if the individual 251 
expresses the HLA allele and is in the IHAC cohort, or 0 otherwise. In this way, we can 252 
obtain a p-value testing the hypothesis that selection is the same in both cohorts (null 253 
hypothesis) or whether selection differs across cohorts (alternative hypothesis). In contrast 254 
to the HLA-AP analyses described thus far, the present one does not feature corrections for 255 
HLA linkage disequilibrium or HIV codon covariation – and therefore will yield odds ratios 256 
of association and p-values that differ slightly from the original cohort-specific values. In 257 
the inter-cohort differential escape analysis, significance was defined as p < 0.01, q < 0.05.258 
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Results 259 
 260 
Identification of HLA-associated polymorphisms in chronically HIV-1 clade 261 
B-infected Japanese individuals. 262 
The first objective of our study was to identify and characterize HLA-AP in Japan, a 263 
unique population in terms of its HLA class I distribution and predominantly HIV clade B 264 
epidemic. Towards this end, we analyzed linked HIV/HLA genotypes from 430 265 
antiretroviral therapy-naive Japanese individuals chronically infected with HIV-1 clade B. 266 
A total of 78 unique HLA class I alleles, defined at subtype-level (4-digit) resolution, were 267 
observed in our cohort (Fig. S1) at frequencies consistent with the published literature (23). 268 
Of these, 37 (including 9 HLA-A, 17 HLA-B, and 11 HLA-C alleles) were observed in at 269 
least 10 individuals, and thus were included in the statistical analysis of HLA-APs (see 270 
methods). Amplification and sequencing of HIV-1 Gag, Pol without the transframe (TF) 271 
protein, and Nef was successful for 397 (92.3%), 363 (84.4%), and 306 (71.2%) individuals, 272 
respectively. As described in the methods, HLA-APs within these three genes were 273 
identified using a phylogenetically corrected logistic regression model which corrects for 274 
the confounding effects of viral phylogeny, HIV-1 codon covariation and linkage 275 
disequilibrium between host HLA class I alleles (16, 17, 20). A false discovery rate 276 
(q-value) approach was employed to address multiple tests. 277 
At a threshold of q < 0.2, a total of 284 HLA-APs, comprising 143 adapted and 141 278 
non-adapted associations, were identified in Gag (N=94), Pol (N=86), and Nef (N=104 279 
associations) (Fig. 1 and Table S1). HLA-APs were more frequently detected in Nef 280 
(occurring at 45 of 206 codons; 21.8%) compared to Gag (51 of 500 of codons; 10.2%) or 281 
Pol (51 of 947 codons; 5.1%). Although HLA class I allele frequencies in Japan are 282 
somewhat distinct globally, the distribution of HLA-AP across HIV-1 proteins was 283 
consistent with that reported in previous studies of other populations infected with clades B 284 
or C (1, 2, 6, 7, 16). Broken down by HLA locus, the numbers of HLA-A-, HLA-B-, and 285 
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HLA-C-associated polymorphisms were 78, 140, and 66, respectively, numbers that were 286 
also consistent with previous reports from Caucasian and African cohorts that HLA-B 287 
alleles restrict more associations than HLA-A or HLA-C alleles (1, 6, 18). 288 
 289 
Correlation between the total number of HLA-associated substitutions and clinical 290 
parameters in Japanese individuals. 291 
We next wished to investigate the relationship between the presence of HLA-associated 292 
substitutions in each gene and patient HIV-1 plasma viral load (pVL) and CD4+ T cell 293 
count (CD4 count) in the Japanese cohort. As described in the methods, substitutions within 294 
a given HIV-1 sequence were counted as “HLA-associated” if they had been identified as 295 
being associated with any HLA class I allele in our study, regardless of the HLA alleles 296 
expressed by the patient. For example, Gag-9S is a HLA-B*15:01-associated nonadapted 297 
polymorphism (Fig. 1 and Table S1); as such, any amino acid other than “S” at codon 9 298 
was counted as an HLA-associated substitution. Similarly, Gag-123G is an 299 
HLA-C*01:02-associated adapted polymorphism (but no specific nonadapted forms, 300 
restricted by C*01:02 or others, were identified at this position); as such, any sequence 301 
harboring “G” at codon 123 was counted as having an HLA-associated substitution at this 302 
site. 303 
A weak yet statistically significant inverse correlation was observed between pVL and 304 
the total number of HLA-associated substitutions in Pol (Spearman’s R = −0.11; p = 0.04) 305 
(Fig. 2A). However, no such correlations were observed for Gag (Spearman’s R= −0.056, p 306 
= 0.3) or Nef (Spearman’s R= −0.029, p = 0.6) (Fig. 2A). Moreover, no significant 307 
correlations were observed between the total number of HLA-associated substitutions in 308 
any HIV protein, and CD4 count (Fig. 2A). Though the overall association is weak, results 309 
raise the intriguing hypothesis that selection of certain HLA-driven substitutions in Pol 310 
could modulate VL in the Japanese population. 311 
We next wondered whether the observed correlation between Pol polymorphisms and 312 
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lower pVL could be attributed to polymorphisms restricted by HLA alleles that are 313 
protective in Japanese populations. HLA-B*67:01 and the HLA-B*52:01-HLA-C*12:02 314 
haplotype are examples of such protective alleles (24). As such, we investigated whether 315 
they could play a role in the observed pVL correlation. No HLA-B*67:01-associated 316 
substitution was identified in Pol, whereas four HLA-B*52:01-associated and one 317 
HLA-C*12:02-associated substitutions were detected in this protein (Table S1). Exclusion 318 
of the single HLA-C*12:02-associated substitution from analysis did not affect the 319 
relationship between the number of HLA-associated substitutions in Pol and pVL (data not 320 
shown). In contrast, exclusion of the four HLA-B*52:01-associated Pol substitutions 321 
substantially weakened the overall relationship between the number of HLA-associated Pol 322 
substitutions and pVL (Spearman’s R = −0.057; p = 0.3) (Fig. 2B). Similarly, specific 323 
consideration of only HLA-B*52:01-associated Pol substitutions revealed a highly 324 
significant inverse correlation with pVL (Spearman’s R = −0.18; p = 0.0007) (Fig. 2C) that 325 
represented the strongest such relationship detected in Pol for common HLA alleles 326 
observed in our cohort (Fig. S2). We therefore reasoned that B*52:01-restricted 327 
substitutions were likely to be critical mediators of the observed pVL effect.  328 
Finally, stratification of B*52:01-associated Pol substitutions by host B*52:01 329 
expression revealed that the inverse correlation with pVL remained strongly detectable in 330 
HLA-B*52:01− individuals (Spearman’s R = −0.18; p = 0.003), but not in HLA-B*52:01+ 331 
individuals (Spearman’s R = 0.026; p = 0.8) (Fig. 2D). We interpret our observations to 332 
suggest that HLA-B*52:01-restricted Pol substitutions possess fitness costs that manifest 333 
themselves in terms of lower pVL upon transmission to, and persistence in, HLA-B*52:01− 334 
individuals. In contrast, no such pVL effects are detectable in B*52:01+ individuals, likely 335 
because the fitness costs of these substitutions are outweighed by the advantages conferred 336 
by immune escape. 337 
 338 
Differential escape between HLA subtypes in Japanese individuals. 339 
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Our final goal in characterizing HLA-AP in Japan was to investigate the extent of 340 
differential escape between closely-related HLA subtypes. In particular, we hypothesized 341 
that HLA subtype members differing with respect to amino acids located within in the 342 
peptide-binding groove of the HLA molecule may differ with respect to the nature (or 343 
binding affinity) of the specific HIV epitopes presented (25-28), and therefore that they 344 
may exhibit differential escape pathways. In contrast, HLA subtype members that differ 345 
with respect to amino acids located outside the peptide-binding groove may be more likely 346 
to present the same epitopes (29-31), and therefore will generally exhibit less evidence for 347 
differential escape between them. Of the 284 HLA-AP identified in our cohort, 128 were 348 
restricted by HLA allele groups (A*02, A*26, B*15, B*40, C*03, C*08, and C*14) 349 
containing two or more subtype members (Table S1). For five of these allele groups (A*02, 350 
A*26, B*15, B*40, and C*08), subtype members differed by substitutions within the 351 
peptide-binding groove (Fig. S3), supporting them as potential candidates for differential 352 
HLA-AP selection. In contrast, members of the C*03 and C*14 subtypes differed by 353 
substitutions outside the peptide-binding groove (Fig. S3), suggesting that their epitope 354 
repertoire (and thus escape pathways) would be more similar to one another. 355 
We began by simply comparing HLA-AP identified in context of the different HLA 356 
subtypes. As expected, viral polymorphisms associated with HLA subtype members 357 
differing within their peptide-binding grooves appeared to be quite specific to each HLA 358 
subtype (Fig. S3A, S3B, S3C, S3D, and S3F). Surprisingly however, viral polymorphisms 359 
associated with HLA subtype members differing only with respect to amino acids located 360 
outside their peptide-binding grooves also appeared to be quite specific to each HLA 361 
subtype (Fig. S3E and S3G). For example, HLA-C*03:03 and C*03:04, which differ only 362 
by substitutions at position 91 that have no contact with the groove (29-31), were 363 
associated with a total of 11 HLA-APs, none of which appeared to be shared (Fig. S2E). 364 
Similarly, HLA-C*14:02 and C*14:03, that differ only by a substitution at position 21 365 
located outside of the floor of the peptide-binding groove (Fig. S2G), shared only 10 of the 366 
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24 HLA-APs identified between them. 367 
However, qualitative comparisons of HLA-AP meeting a specific significance threshold, 368 
such as those described above, are not statistically robust (since individual associations may 369 
fail to meet the threshold and thus not be detected, or variations in allele frequency may 370 
limit power to detect associations). Thus, to explicitly investigate whether the above 371 
examples represent statistically significant instances of differential escape between subtype 372 
members we applied a phylogenetically-corrected interaction test to compare their strengths 373 
of selection between subtypes (17). For each HLA allele group, we took the union of all 374 
HLA-AP identified for all subtype members, and compared their strength of selection 375 
between all subtype members in a pairwise manner. Representative examples of our results 376 
are shown in Fig. 3. For example, HLA-A*26:01 or A*26:03 differ with respect to 377 
substitutions at amino acids 74, 76 and 77, located within the peptide-binding groove of the 378 
of the HLA molecule (Fig. S3B). A total of 10 HLA-APs, located at 8 HIV codons, were 379 
originally identified as associated with either HLA-A*26:01 or A*26:03 (Fig. S3B). 380 
Although qualitatively, all 10 HLA-APs appear to be differentially selected by 381 
HLA-A*26:01 or A*26:03 (Fig. S3B), the phylogenetically-corrected interaction test 382 
revealed only 3 of them (located at Pol residues 276 and 551, and Nef residue 85) to be 383 
significantly differentially selected in terms of their natural logarithm of the odds ratios of 384 
association (p < 0.05, q < 0.2) (Fig. 3A). Surprisingly, significant differential escape was 385 
also observed between subtype members that differed only with respect to substitutions 386 
outside of their peptide-binding grooves: 3 of 9 (33.3%) sites restricted by HLA-C*03 387 
allele group members and 5 of 14 (35.7%) sites restricted by C*14 allele group members 388 
similarly exhibited statistically significant evidence of differential selection (Fig. 3B and 389 
3C). 390 
To compare whether the extent of differential escape between HLA subtype members 391 
varied between HLA allele groups that differed with respect to substitutions within or 392 
outside the binding groove, we asked whether the extent of differential escape between 393 
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subtype members of the former group (comprising A*02, A*26, B*15, B*40, and C*08) 394 
differed compared to the latter group (comprising HLA-C*03 and C*14). Overall, we found 395 
no significant differences in the proportion of differential escape between them (34.8% for 396 
HLA-C*03/C*14 subtypes compared to 36.8% for subtypes of all other HLA alleles, p = 397 
0.5) (Table S2). This intriguing result suggests that variations outside the HLA binding 398 
groove may contribute as much to differential escape as variations within the binding 399 
groove. 400 
 401 
Comparison of HLA-APs between Japanese and non-Asian individuals chronically 402 
infected with HIV-1 clade B.  403 
Our second objective was to investigate HLA-AP identified in Japan versus those 404 
previously identified in non-Asian cohorts infected with HIV clade B. The comparison 405 
cohort in this analysis was the International HIV Adaptation Collaborative (IHAC) cohort, 406 
comprising 1,888 antiretroviral-naïve individuals with chronic clade B infection in Canada, 407 
the USA, and Australia (of which <5% of cohort participants are Asian) (16). 408 
HLA-AP will differ to some extent between human populations due to the presence (or 409 
enrichment) of certain HLA alleles in one population versus another. Indeed, HLA allele 410 
frequencies differed markedly between the Japan and IHAC cohorts (Fig. S1). As such, we 411 
begin with a qualitative comparison of HLA-AP between them. We begin with a simple 412 
positional analysis. In the Japanese cohort, HLA-APs were observed at a total of 147 codon 413 
positions in Gag, Pol, and Nef (Fig. 4). Of these, 117 (79.6%) were also associated with at 414 
least one HLA allele in IHAC. In contrast, the remaining 30 positions (including 16, 7 and 415 
7 in Gag, Pol, and Nef, respectively) that harbored HLA associations in Japan were not 416 
associated with any HLA alleles in IHAC (Fig. 4). That 30/147 (20.4%) of HIV codons 417 
exhibited evidence of HLA-driven selection in Japan but not IHAC already strongly 418 
suggests that HIV is evolving under population-specific selection pressures in Japan 419 
compared to other regions. 420 
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Next we compared HLA-AP over HIV position and specific HLA restriction. Of the 284 421 
HLA-APs identified in Japan, 188 (66.2%) were not reported in IHAC. As expected, a 422 
substantial portion of these (46 of 188, 24.5%) were associated with 8 HLA subtypes 423 
(A*26:03, B*40:06, B*54:01, B*55:02, B*59:01, B*67:01, C*08:03, and C*14:03) 424 
common in Japan but essentially absent (<1% frequency) in IHAC. Others were likely 425 
attributable to alleles observed at much higher frequencies in Japan compared to IHAC: for 426 
example, an additional 27.1% were associated with HLA alleles present in both cohorts, but 427 
whose frequencies were at least fourfold higher in Japan compared to IHAC. Overall, 428 
results suggest that HLA-APs identified in Japan are quite distinctive, in large part 429 
reflecting the unique HLA allele distribution in the Japanese population. 430 
We also wished to investigate the existence of differential HLA-associated escape 431 
pathways between the two populations, that are not attributable to HLA frequency 432 
differences between them – in other words, cases where the same HLA subtypes drive 433 
significantly different escape pathways in Japan versus IHAC cohorts. This required the 434 
application of statistical tests (see methods and below). Specifically, we first identified a list 435 
of N=551 HLA-AP in HIV Gag, Pol and Nef, which represented the union of all HLA-AP 436 
identified in either Japan or IHAC for which both the viral polymorphism and the 437 
restricting HLA allele were observed in a minimum of 10 individuals per cohort (not 438 
shown). The latter criteria were employed in order to achieve some minimal statistical 439 
power to compare strengths of individual associations between cohorts. It is important to 440 
emphasize that these criteria would by definition exclude HLA alleles (and/or viral 441 
polymorphisms) present in one cohort but essentially absent in the other (as we would have 442 
no power, and in fact no rationale, to test whether their strengths of selection were 443 
statistically significantly different between cohorts). 444 
For each HLA-AP, we calculated its natural logarithm of the odds ratio (lnOR) of 445 
association in each cohort – a measure that can be interpreted as an estimate of the strength 446 
of selection exerted by the HLA allele on that particular HIV codon, in that cohort. We then 447 
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applied a phylogenetically-corrected interaction test (17) to assess whether these lnORs of 448 
selection were significantly different in the Japanese versus the IHAC cohorts. In these 449 
analyses, statistical significance was defined as p < 0.01 and q < 0.05. 450 
Overall, 71 (of 551, 12.8%) HLA-APs originally identified in either Japan or IHAC 451 
cohorts exhibited significantly different strengths of selection between the two populations 452 
(Figure 5 and Table S3). The HLA-B*44:03-associated 125H substitution in Nef serves as 453 
an example of how to interpret these data. The lnOR of this association is 1.73 in Japan 454 
(with a cohort-specific p-value of 3.26 × 10−6) versus 0.42 for IHAC (with a cohort-specific 455 
p-value of 0.36). Both lnORs are positive, indicating that 125H is positively associated with 456 
B*44:03 in both cohorts, but the higher lnOR in Japan indicates that the strength of 457 
selection of Nef-125H by B*44:03 is greater in Japan compared to IHAC (indeed, the 458 
cohort-specific p-values reveal that this association is significant in Japan but not IHAC). 459 
Finally, the p- and q-values for the intercohort comparison (p = 1.02 × 10−6 and q = 1.19 × 460 
10−4; Table S3) confirm that the strength of selection of Nef-125H by B*44:03 is 461 
significantly greater in Japan compared to IHAC. Importantly, this difference is not simply 462 
attributable to intercohort differences in B*44:03 frequency (which is comparable between 463 
populations; Fig S1).   464 
In addition to the HLA-B*44:03-associated 125H polymorphism in Nef, we identified 465 
21 other HLA-AP whose strengths of selection were significantly greater in Japan 466 
compared to IHAC, yielding a total of 22 (of 71; 31.0%) HLA-APs in this category. 467 
Conversely, 39 (of 71; 54.9%) differentially-selected HLA-AP exhibited strengths of 468 
selection that were greater in IHAC compared to Japan. The HLA-A*26:01-associated 469 
889S substitution in Pol serves as an example. The lnOR of this association is −0.18 in 470 
Japan (with a cohort-specific p-value of 0.3) versus −1.17 for IHAC (with a cohort-specific 471 
p-value of 7.92 × 10−9). Both lnORs are negative, indicating that 889S is negatively 472 
associated with A*26:01 in both cohorts, but the more negative value for IHAC indicates 473 
that this association is stronger in IHAC compared to Japan. Finally, the p- and q-values for 474 
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the intercohort comparison (p = 1.15 × 10−4 and q = 4.48 × 10−3; Table S3) confirm that of 475 
the strength of the negative association between Pol-889S by A*26:01 is significantly 476 
greater in IHAC compared to Japan.  477 
Strikingly, the remaining 10 (of 71; 14.1%) differentially-selected HLA-APs displayed 478 
diametrically opposed directions of selection between the cohorts (defined here as lnORs of 479 
association that were positive in one cohort but negative in the other, where the 480 
cohort-specific p-values were <0.05 in both cases) (Fig. 5). The HLA-B*44:03-associated 481 
120F substitution in Nef serves as an example. The lnOR of this association is 1.44 in Japan 482 
(with a cohort-specific p-value of 2.03 × 10−4), indicating that HLA-B*44:03 is 483 
significantly positively associated with 120F in Japan. In contrast, the lnOR of this 484 
association is −0.69 in IHAC (with a cohort-specific p-value of 9.50 × 10−3), indicating that 485 
HLA-B*44:03 is significantly negatively associated with 120F in Japan. The p- and 486 
q-values for the intercohort comparison (p = 2.15 × 10−8 and q = 3.75 × 10−6; Table S3) 487 
confirm that the opposing direction of selection of Nef-120F by B*44:03 between Japanese 488 
and IHAC cohorts is a statistically significant observation. 489 
Of interest, the 71 HLA-APs identified as being under significantly different selection 490 
between Japan and IHAC cohorts were differentially distributed across HLA loci and HIV 491 
proteins (Fig. 6A and 6B). Specifically, HLA-A-associated polymorphisms that were 492 
significantly differentially selected across cohorts were most abundant in Gag, followed by 493 
Pol and Nef, whereas differentially-selected HLA-B-associated and HLA-C-associated 494 
polymorphisms were most numerous in Nef, followed by Pol and Gag. Taken together, 495 
results support the existence of HLA class I alleles that drive significantly different HIV 496 
escape pathways in global populations infected with the same viral clade. The uneven 497 
distribution of the locations of these differentially-selected polymorphisms across HLA loci 498 
and HIV regions raise the intriguing hypothesis that Gag and Pol/Nef may differentially 499 
evolve under selection pressures dominated by HLA-A versus HLA-B/C allele-restricted 500 
immune responses, respectively.   501 
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Discussion 502 
 503 
The present study comprised two major objectives, both of which are novel in terms of 504 
populations studied and/or analytical methods used. First, we characterized HLA-AP in 505 
HIV-1 clade B Gag, Pol and Nef and their relationship with clinical parameters in a large 506 
Japanese cohort. Second, we compared HLA-AP in Japanese versus non-Asian populations 507 
infected with HIV clade B, to identify population-specific differences in their selection. In 508 
particular, we wished to identify HLA-AP that are unique to Japan by virtue of the 509 
distinctive HLA distribution in this population, as well as cases where the same HLA allele 510 
drives divergent escape pathways in Japan vs. non-Asian populations. 511 
This study is the first to identify HLA-APs in HIV-1’s structural and functional genes in 512 
Japanese populations. Only one previous study investigated HLA-AP in HIV-1 clade 513 
B-infected Asians (11): this study comprised 231 Chinese individuals infected during a 514 
narrow-source outbreak, and identified 141 HLA-associated polymorphisms at two-digit 515 
resolution. Our study differs from the latter with respect to cohort size, HLA genetics of the 516 
host population, HLA typing resolution and epidemiology of the epidemic. Using 517 
phylogenetically-informed approaches, we identified 284 HLA-APs within HIV-1 Gag, Pol 518 
and Nef in our cohort, supporting a strong influence of population-specific, HLA-driven 519 
immune pressures in shaping HIV-1 evolution in Japan. In contrast to a previous study 520 
undertaken in a predominantly Caucasian population that observed approximately one-half 521 
of the total number of Gag HLA-APs to be located within or flanking reported CTL 522 
epitopes (3), the majority of HLA-APs identified in the present study were not located 523 
nearby reported CTL epitopes. This discrepancy may be due to the limited number of 524 
Asian-specific HLA-restricted CTL epitopes identified to date, underscoring the need for 525 
further epitope discovery in these populations. 526 
This study revealed differential frequencies of HLA-APs across HIV genes in the 527 
Japanese population. Consistent with previous studies of HLA-AP in HIV clade B (2, 16, 528 
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18), HLA-APs were more frequently detected in Nef than in Gag and Pol. Also consistent 529 
with previous observations in Caucasian, African, Chinese, and Mexican populations (1, 6, 530 
11, 15, 18), the number of HLA-B-associated polymorphisms in our cohort was higher than 531 
that of HLA-A- or HLA-C-associated ones, further supporting a dominant role of HLA-B 532 
in HIV evolution (32). An interesting feature of the Japanese population is that 533 
approximately 70% of individuals carry HLA-A*24:02 (23). Despite sufficient statistical 534 
power to detect HLA-A*24:02-associated polymorphisms in our cohort, we identified only 535 
9 of these, 6 of which were located in epitopes identified by our group (33-35). A possible 536 
explanation for the relatively low number of A*24:02-associated polymorphisms in Japan is 537 
that they have accumulated over time in circulating sequences such that they are no longer 538 
significantly enriched among persons expressing HLA-A*24:02. Further analysis of 539 
mutations selected by HLA-A*24:02-restricted CTLs should clarify the mechanism 540 
whereby high frequency HLA alleles influence the formation of HIV-1 polymorphisms. 541 
Protective HLA alleles such as HLA-B*57, B*58, and B*27, select Gag mutations 542 
affecting viral replication in Caucasians and Africans (36-41) that may also provide some 543 
clinical benefit if they are transmitted to hosts lacking these alleles (42, 43). HLA-B*57, 544 
B*58, and B*27 are not present at appreciable frequencies in Japan (23). It is therefore 545 
perhaps unsurprising that no correlations between HLA-associated substitutions in Gag and 546 
HIV clinical parameters were observed in our cohort. In contrast, we observed a weak but 547 
significant inverse correlation between the frequency of HLA-APs in Pol and plasma viral 548 
load, which appeared to be driven by polymorphisms selected by HLA-B*52:01, an allele 549 
identified as protective in Japan (24). Upon further stratification by HLA-B*52:01 550 
expression, the inverse correlation between VL and the total number of B*52:01-associated 551 
Pol substitutions was maintained in HLA-B*52:01−, but not in HLA-B*52:01+ individuals. 552 
Taken together, these findings suggest that transmitted B*52:01-associated polymorphisms 553 
could reduce viral fitness in a dose-dependent manner, though further studies would be 554 
required to assess this. In addition, these substitutions were not located within or nearby 555 
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known B*52:01-restricted epitopes. Thus, further research would be required to identify 556 
these epitopes and elucidate their mechanisms of escape. 557 
Many previous studies of HLA-APs were performed at 2-digit HLA resolution (1-4, 6). 558 
Here, we performed HLA genotyping at 4-digit resolution, which allowed us to investigate 559 
differential escape between closely-related HLA subtypes in the Japanese cohort. Nearly 560 
one half of the HLA-AP identified in Japan were restricted by HLA allele groups 561 
containing two or more subtype members (A*02, A*26, B*15, B*40, C*03, C*08, and 562 
C*14). For five of these groups (A*02, A*26, B*15, B*40, and C*08), subtype members 563 
differed by substitutions within the peptide-binding groove, while for the remaining two 564 
groups (HLA-C*03 and -C*14), subtype members differed by substitutions located outside 565 
the peptide binding groove. Reasoning that amino acid differences located within the 566 
peptide-binding groove could modulate the nature or presentation of CTL epitopes, we 567 
hypothesized that the former group would generally exhibit distinct HLA-AP between 568 
subtype members, while the latter would generally exhibit similar or identical HLA-AP. 569 
However, we were surprised to observe substantial evidence for differential HLA-AP 570 
selection between closely-related HLA subtypes regardless of whether they differed in 571 
sequence within or outside the peptide binding groove. Significantly differential HLA-AP 572 
selection was observed at 3 of 9 HLA-C*03 associated sites and 5 of 14 HLA-C*14 573 
associated sites (Fig. 3), proportions that were not significantly lower than the frequency of 574 
differential selection between subtypes that differed in their peptide-binding groove.  575 
This observation raised several hypotheses. HLA polymorphic sites outside the 576 
peptide-binding groove may indirectly influence the binding groove conformation, thus 577 
altering HLA-peptide interactions and/or T cell recognition. Another possibility is selection 578 
by NK cells, as KIR may recognize sites outside the peptide-binding groove. Indeed, 579 
KIR3DL1 bind to the loop including position 91 of HLA-B*57:01 (44). However it is not 580 
clear whether KIR2DLs, which are receptors for HLA-C, can bind to the loop outside the 581 
peptide-binding groove of HLA-C molecules. A recent study showed that HLA-C antigens 582 
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are expressed at different levels on the cell surface, even among HLA-C subtypes (45). 583 
This study also observed a strong positive correlation between HLA-C expression level and 584 
the strength of HLA-C-mediated selection pressure conferred on HIV. Differential 585 
expression levels of these HLA-C subtype members in Japanese populations thus provide 586 
another potential explanation for this observation, for future follow-up. 587 
Our second objective was to investigate differential HLA-AP between Japanese and 588 
non-Asian cohorts infected with HIV clade B. Here, the IHAC cohort (comprising clade 589 
B-infected Canadians, Americans and Australians) was used as a comparison group (16). 590 
HLA-AP identified in human populations will differ to some extent due to 591 
population-specific HLA distributions, yielding population-specific HLA-AP driven by 592 
HLA alleles present in one population but not another (15). Indeed, two-thirds of the 593 
HLA-APs identified in Japan had not previously been identified due to the presence of the 594 
restricting HLA alleles in Japan, but its absence (or far lower prevalence) in IHAC. 595 
What remains unknown however, is the extent to which the same HLA allele may drive 596 
significantly different escape pathways in different human populations. To this end, we 597 
applied novel phylogenetically-corrected statistical approaches to assess the extent to which 598 
HLA-AP identified in either Japan or IHAC, that were restricted by HLA alleles present in 599 
both populations, exhibited significantly different strengths of selection between them. Of 600 
the 551 HLA-AP investigated, 71 (12.9%) were significantly differentially selected in 601 
Japan versus IHAC at a stringent statistical threshold of q < 0.05. Of these 71, 31% 602 
exhibited significantly greater strengths of selection in Japan compared to IHAC whereas 603 
55% exhibited greater strengths of selection in IHAC compared to Japan. Surprisingly, the 604 
remaining 14% displayed diametrically opposed selection pathways in the two cohorts 605 
(where an HIV polymorphism represented the “adapted” form associated with a given allele 606 
in one cohort, but the “nonadapted” form associated with the same allele in the other 607 
cohort). It is important to emphasize that these significantly different pathways of HLA-AP 608 
selection are not simply attributable to differences in HLA frequency between the cohorts. 609 
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We feel that these are intriguing observations that merit further study. Nevertheless we 610 
propose the following potential interpretations. Firstly, these differences could be explained 611 
by functional differences in HIV-1 specific T cells elicited between Japanese and Caucasian 612 
cohorts, possibly as a result of differences in host genetics (for example in the genes that 613 
encode the T-cell receptor and/or modulate their expression). Such differences may 614 
influence the structure of the T-cell receptor(s) and thus the quality, quantity and/or makeup 615 
of the HIV-1 specific T cell repertoire, thus influencing the specific escape mutations 616 
selected in context of peptide-bound HLA. Further analysis of HIV-1 specific T cells 617 
driving the selection of these mutants in both cohorts is therefore warranted. It is also 618 
important to note that the intercohort HLA-AP comparisons, unlike previous analyses, did 619 
not correct for HLA linkage disequilibrium (LD) or HIV codon covariation. Although both 620 
Japan and IHAC cohorts feature HIV clade B infections, intra-clade differences in the viral 621 
backbone could also influence differential escape via epistatic effects. In-depth analyses of 622 
intercohort differences in HIV codon covariation relationships are also therefore warranted. 623 
Intercohort differences in HLA linkage disequilibrium are another possible contributor. 624 
Finally, the differentially-selected HLA-AP between cohorts appeared to be unevenly 625 
distributed by HLA locus: while HLA-A associated polymorphisms exhibiting differential 626 
selection between cohorts were more abundant in Gag compared to other proteins, HLA-B 627 
and HLA-C associated polymorphisms exhibiting differential selection between cohorts 628 
tended to be more abundant in Nef. This suggests that inter-cohort differential HLA-APs 629 
across HIV proteins may be arising as a result of cellular immune pressures exerted by 630 
distinct HLA class I loci, though this also requires further study. 631 
Nevertheless, the present study confirms of the existence of population-specific HIV-1 632 
adaptations that are attributable to the unique HLA allele distributions of that population 633 
(15). We additionally provide evidence of population-specific HIV adaptation to 634 
HLA-restricted immune responses that cannot be explained by differential HLA frequencies 635 
alone: cases where the same HLA allele drives significantly different, sometimes opposing, 636 
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escape pathways in different host populations. Taken together, results support differential 637 
HIV-1 adaptation to human populations worldwide, that might be driven by multiple host 638 
and viral mechanisms.  639 
 27
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Figure legends 852 
 853 
FIG 1 Escape Map of HLA-associated polymorphisms for Gag, Pol, and Nef. 854 
Escape maps indicate the locations, specific residues and HLA restrictions of 855 
HLA-associated polymorphisms (all q < 0.2). The global HIV-1 clade B consensus amino 856 
acid sequence is used as a reference. Shaded vertical bars separate blocks of 10 amino acids. 857 
“adapted” amino acids (those significantly overrepresented in the presence of a given HLA 858 
allele) are red. “nonadapted” amino acids (those significantly underrepresented in the 859 
presence of a given HLA allele) are blue. Polymorphisms associated with the same HLA 860 
allele that occur in proximity to one another are grouped together in yellow boxes. A list of 861 
all HLA-associated polymorphisms is provided in Table S1. 862 
 863 
FIG 2 Correlation between HLA-associated substitutions in Gag, Pol, and Nef and 864 
viral load or CD4 count. 865 
The total number of HLA-associated substitutions in each subject’s Gag, Pol, and Nef 866 
sequence was counted (see methods). (A) Correlation between the number of 867 
HLA-associated substitutions in Gag, Pol or Nef and pVL or CD4 count, (B) Correlation 868 
between pVL and the number of HLA-associated substitutions in Pol, with 869 
HLA-B*52:01-associated substitutions excluded (C) Correlation between pVL and the 870 
number of HLA-B*52:01-associated substitutions in Pol (all patients). (D) Correlation 871 
between the number of HLA-B*52:01 associated substitutions in Pol in 872 
HLA-B*52:01-positive individuals (left panel) and HLA-B*52:01-negative individuals 873 
(right panel). Analyses were performed using Spearman’s correlation. Linear regression 874 
lines are included in the plots. 875 
 876 
FIG 3 Polymorphic positions in HLA class I molecules and differential escape between 877 
pairs of HLA subtypes. 878 
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In each ribbon diagram depicting the HLA-peptide-binding groove, the locations of 879 
residues differing among subtype members of the (A) HLA-A*26, (B) HLA-C*03, and (C) 880 
HLA-C*14 allele groups are highlighted in red and labeled with their locations and amino 881 
acids. HLA-AP comparisons between subtype members are shown in the corresponding 882 
plot below. Horizontal bars represent the natural logarithm of the odds ratio (lnOR), with 883 
colors indicating the restricting allele. Infinite lnORs are set to values of ±4. Boldface type 884 
indicates HLA-AP whose strengths of selection are statistically significantly different 885 
between the two subtype members (p < 0.05, q < 0.2). 886 
 887 
FIG 4 Location of HLA-associated sites common to HIV-1 clade B-infected Japanese 888 
and Caucasian cohorts, and those unique to Japan. 889 
The locations of all HLA-APs in Gag (500 codons), Pol (1,003 codons), and Nef (206 890 
codons) are illustrated. The residues in the Pol transframe protein (TF) were not analyzed in 891 
IHAC and are thus excluded (grey bar). Blue squares identify codons that harbored at least 892 
one HLA-AP in both Japanese and IHAC cohorts. Red squares indicate codons that 893 
harbored HLA-AP in Japan, but that were not associated with any HLA alleles in IHAC. 894 
 895 
FIG 5 HLA-AP displaying significantly different strengths of selection between 896 
Japanese and IHAC cohorts. 897 
A phylogenetically-corrected interaction test was used to compare the natural logarithm 898 
of the odds ratio (lnOR) of selection of HLA-APs in the Japanese cohort versus the IHAC 899 
cohort. Comparisons with a p < 0.01 and q < 0.05 are reported. Bars represent the lnOR. 900 
Infinite lnORs are set to values of ±4. Boldface type indicates HLA-AP that display 901 
diametrically opposed directions of selection between the cohorts (defined here as lnORs of 902 
association that were positive in one cohort but negative in the other, where the 903 
cohort-specific p-values were <0.05 in both cases). The complete list of all comparisons 904 
with p < 0.05 is available in Table S3 in the supplemental material. 905 
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 906 
FIG 6 HLA-AP identified as being under differential strength of selection in Japanese 907 
and IHAC cohorts. 908 
At a threshold of p < 0.01, q < 0.05, a total of 71 HLA-APs were identified as being 909 
under significantly different strengths of selection in Japanese and IHAC cohorts. The 910 
restricting HLA alleles and their HIV-1 protein locations are shown in (A). The number of 911 
differentially-selected HLA-AP, broken down by HLA locus and HIV-1 protein, is shown 912 
in (B). 913 






